Research Programs
Driving Breakthroughs in Cancer Immunotherapy Research
The Cancer Research Institute (CRI) funds pioneering cancer immunotherapy research through a global portfolio of immuno-oncology grants. Our funding programs support scientists – from postdoctoral fellows to established investigators – who are driving innovation in our tumor immunology, immune cell biology, and translational cancer research.
Our competitive cancer research grants include:
- Postdoctoral Fellowships: Mentored support for early-career researchers.
- CRI STARs: Support for mid-career scientists pursuing bold immunotherapy research.
Join the global community of CRI-funded scientists accelerating the next generation of immunotherapy breakthroughs.
CRI Irvington Postdoctoral Fellowship
Career development and support for laboratory research for promising young immunologists
Application Deadline
March 1; September 1
CRI Irvington Postdoctoral Fellowship to Promote Racial Diversity
Career development and support for laboratory research for underrepresented scientists in immuno-oncology
Application Deadline
March 1; September 1
CRI Immuno-Informatics Postdoctoral Fellowship
Support for qualified young scientists who wish to receive dual training in immunology and data science
Application Deadline
March 1; September 1
Lloyd J. Old STAR Program
Mid-career support for the future “stars” in cancer immunology
Application Deadline
January 15
Total Funding
$1.25M
CRI Awards & Honors
Each year, CRI bestows its highest scientific honors – The William B. Coley Award for Distinguished Research in Basic and Tumor Immunology, and the Frederick W. Alt Award for New Discoveries in Immunology – upon leading scientists whose research has made a significant impact on the fields of immunology and cancer immunotherapy.
CRI Funded Scientists
These current and future scientific leaders in immunology and tumor immunology, from top academic research institutions, are advancing fundamental and applied discoveries that impact cancer research. From bench to bedside, CRI is ushering in the next generation of cancer immunotherapy innovations.